文献速递创伤与烧伤复苏、休克与脓毒症

冻干血浆用于严重创伤:系统评价与meta分析

Freeze-dried plasma for major trauma - Systematic review and meta-analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论在创伤患者中,冻干血浆(FDP)与新鲜冰冻血浆(FP)相比,死亡率和同种异体血制品输注无差异,FDP可行且未报告不良事件。

两项研究(n=119)合并分析显示,FDP与FP相比,死亡率(合并OR 0.66,95%CI 0.29-1.49,I2=0%)和同种异体血制品输注均无差异。FDP使用可行,未报告不良事件;动物数据显示FP与FDP在凝血和抗炎特征方面结果相似。证据质量受限于多数为观察性研究、人群异质性(军事和民用创伤)及中等偏倚风险,需前瞻性观察研究或RCT进一步验证。

要点

  • 在创伤患者中,FDP与FP相比死亡率无差异(合并OR 0.66,95%CI 0.29-1.49,I2=0%,基于2项研究n=119)。
  • FDP与FP相比同种异体血制品输注无差异(基于2项研究n=119的meta分析)。
  • FDP使用可行,未报告不良事件。
  • 动物创伤研究显示FP与FDP在凝血因子和抗炎特征方面结果相似。
  • 证据等级为level IV,多数为观察性研究,人群异质(军事和民用创伤),中等偏倚风险,需RCT验证。

适用人群与场景

  • 动物创伤模型(15项动物研究)用于评估凝血和抗炎特征。
  • 原文未提及具体的纳入/排除标准、病情阶段或急诊/ICU/院前场景。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及FDP的具体剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 人群:创伤患者(军事和民用创伤),总体中等偏倚风险。
  • 干预与对照:FDP vs FP。
  • 主要终点(疗效):死亡率合并OR 0.66(95%CI 0.29-1.49,I2=0%,基于2项研究n=119),无差异。
  • 关键次要终点:同种异体血制品输注无差异(基于2项研究n=119的meta分析);FDP可行,未报告不良事件。
  • 动物数据:FP与FDP在凝血和抗炎特征方面结果相似。

证据类型、等级与局限

  • 证据类型:系统评价与meta分析,证据等级level IV。
  • 局限:多数研究为观察性,人群异质(军事和民用创伤),中等偏倚风险;meta分析仅基于2项研究(n=119)。
  • 原文建议需精心设计的前瞻性观察研究或优先RCT来回答FDP对实验室指标(凝血因子水平)、输血(同种异体血制品数量)和临床结局(器官功能障碍、住院时间、死亡率)的影响。

对床旁实践的改变

  • 原文结果提示FDP在创伤患者中可行且未报告不良事件,但死亡率与同种异体血制品输注与FP相比无差异,证据等级低(level IV),不足以改变当前优先使用FP的实践。
  • 适用人群为创伤患者(军事和民用),但原文未明确具体纳入/排除标准,临床决策需谨慎。
  • 常见陷阱:meta分析仅基于2项研究(n=119),多数为观察性研究且中等偏倚风险,结果需谨慎解读,不能作为决策阈值。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Treatment of acute trauma coagulopathy has shifted toward rapid replacement of coagulation factors with frozen plasma (FP). There are logistic difficulties in providing FP. Freeze-dried plasma (FDP) may have logistical advantages including easier storage and rapid preparation time. This review assesses the feasibility, efficacy, and safety of FDP in trauma.

STUDY DESIGN AND METHODS: Studies were searched from Medline, Embase, Cochrane Controlled Trials Register, ClinicalTrials.gov, and Google Scholar. Observational and randomized controlled trials (RCTs) assessing FDP use in trauma were included. Trauma animal models addressing FDP use were also included. Bias was assessed using validated tools. Primary outcome was efficacy, and secondary outcomes were feasibility and safety. Meta-analyses were conducted using random-effect models. Evidence was graded using Grading of Recommendations Assessment, Development, and Evaluation profile.

RESULTS: Twelve human studies (RCT, 1; observational, 11) and 15 animal studies were included. Overall, studies demonstrated moderate risk of bias. Data from two studies (n = 119) were combined for meta-analyses for mortality and transfusion of allogeneic blood products (ABPs). For both outcomes, no difference was identified. For mortality, pooled odds ratio was 0.66 (95% confidence interval, 0.29-1.49), with I2 = 0%. Use of FDP is feasible, and no adverse events were reported. Animal data suggest similar results for coagulation and anti-inflammatory profiles for FP and FDP.

CONCLUSION: Human data assessing FDP use in trauma report no difference in mortality and transfusion of ABPs in patients receiving FDP compared with FP. Data from animal trauma studies report no difference in coagulation factor and anti-inflammatory profiles between FP and FDP. Results should be interpreted with caution because most studies were observational and have heterogeneous population (military and civilian trauma) and a moderate risk of bias. Well-designed prospective observational studies or, preferentially, RCTs are warranted to answer FDP's effect on laboratory (coagulation factor levels), transfusion (number of ABPs), and clinical outcomes (organ dysfunction, length of stay, and mortality).

LEVEL OF EVIDENCE: Systematic review and meta-analysis, level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Mok G, Hoang R, Khan MW, et al. Freeze-dried plasma for major trauma - Systematic review and meta-analysis. J Trauma Acute Care Surg. 2021. PMID: 33507025. doi:10.1097/TA.0000000000003012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。